DOCSLIB.ORG

2020 MED-Project Annual Report County of Alameda, California Unwanted Medicine March 1, 2021 Revised April 1, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 MED-Project Annual Report County of Alameda, California Unwanted Medicine March 1, 2021 Revised April 1, 2021 2020 MED-Project Annual Report County of Alameda, California Unwanted Medicine March 1, 2021 Revised April 1, 2021 Prepared By: MED-Project LLC Submitted To: Alameda County Department of Environmental Health Table of Contents I. Executive Summary ............................................................................................................... 4 II. Participating Producers ........................................................................................................ 5 III. Collection Method and Weight ........................................................................................... 5 A. Kiosks .................................................................................................................................... 5 B. Mail-Back Packages ................................................................................................................. 5 C. Take-Back Events ................................................................................................................... 5 D. Total Weight of Collected Unwanted Medicine ........................................................................... 5 IV. Kiosk Drop-Off Locations, Mail-Back Distribution, and Take-Back Events ......................... 6 A. Kiosk Drop-Off Locations ......................................................................................................... 6 B. Mail-Back Package Distribution Locations .................................................................................. 6 C. Number of Mail-Back Packages Provided to Home-Bound and Under Served Residents ................ 6 D. Take-Back Events ................................................................................................................... 6 V. Disposal Information ............................................................................................................ 6 A. Disposal Facility Information .................................................................................................... 6 VI. Compliance with Plan Policies ............................................................................................. 7 VII. Safety and Security Report ................................................................................................ 7 VIII. Educational Efforts and Public Outreach .......................................................................... 7 A. Public Education Activities ....................................................................................................... 7 B. Outreach Activities .................................................................................................................. 7 C. Evaluation Activities ................................................................................................................ 8 IX. Program Goals ..................................................................................................................... 8 A. Collection Goals ...................................................................................................................... 8 B. Education and Public Outreach Goals ....................................................................................... 9 C. Collector Outreach .................................................................................................................. 9 Appendix A .............................................................................................................................. 12 List of Participating Producers ...................................................................................................... 12 Appendix B .............................................................................................................................. 33 Kiosk Drop-Off Site Locations ....................................................................................................... 33 Collection Point Collected Unwanted Products by Weight and Pick-Ups ........................................... 37 Appendix C .............................................................................................................................. 40 Mail-Back Packages Distributed Directly to Residents ..................................................................... 40 Appendix D .............................................................................................................................. 41 Take-Back Events ....................................................................................................................... 41 Appendix E .............................................................................................................................. 42 Disposal Facilities ........................................................................................................................ 42 Appendix F............................................................................................................................... 43 Plan Deviation Report .................................................................................................................. 43 Appendix G .............................................................................................................................. 45 Safety and Security Report .......................................................................................................... 45 Appendix H .............................................................................................................................. 46 MED-Project Brochure and Posters ............................................................................................... 46 2 Appendix I ............................................................................................................................... 61 MED-Project Website Pages ......................................................................................................... 61 Appendix J ............................................................................................................................... 70 MED-Project Website Statistics ..................................................................................................... 70 Appendix K .............................................................................................................................. 71 Brochure and Poster Distribution .................................................................................................. 71 Appendix L ............................................................................................................................... 72 Social Media and Promotion Activity ............................................................................................. 72 Social Media Posts ....................................................................................................................... 72 Email Blast Activity ...................................................................................................................... 78 Appendix M.............................................................................................................................. 79 Media Outreach Summary ........................................................................................................... 79 3 I. Executive Summary Regulations Sec. 15.C.i. “The purpose of the Executive Summary is to provide a broad understanding of the Plan as a whole and content for the data and information that will follow. This Summary should include a brief description of collection and disposal efforts during the reporting period. The executive summary should also include a description of proposals to improve collection efforts and challenges encountered during the reporting period, and how they will be addressed. (Security issues must be addressed separately as set forth below.)” MED-Project LLC (“MED-Project”) operates a Product Stewardship Plan for Unwanted Medicine from Households (“Plan”) in the County of Alameda (“Jurisdiction”) under the Alameda County General Ordinance Code, Chapter 6.53, the Alameda County Safe Drug Disposal Ordinance (“Ordinance”) and the Alameda County Safe Drug Disposal Regulations (“Regulations”). This 2020 County of Alameda Annual Report (“Report”) describes the activities of MED-Project between January 1, 2020, and December 31, 2020 (“Reporting Period”) in compliance with Ordinance Section 6.53.080. All capitalized terminology not defined in this Report is derived from the approved Plan dated February 15, 2019 and amended March 27, 2019. A notice of temporary closure of a disposal facility was sent on October 4, 2019, informing the Jurisdiction of the alternative disposal facilities to be used during the facility’s maintenance closure. On February 29, 2020, MED-Project sent notice of the resumption of operations at the disposal facility and that MED-Project was again disposing of Unwanted Medicine at the disposal facility. MED-Project sent to the Jurisdiction an initial COVID-19 response notification on March 17, 2020, and a second COVID-19 response notification with additional information on March 26, 2020. On April 15, 2020, MED-Project provided a third COVID-19 response notification, including then-current information on restricted access to sites. On July 16, 2020 MED-Project provided a fourth COVID-19 response notification, including then-current information on restricted access to sites. On November 13, 2020, MED-Project submitted a fifth COVID-19
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000
    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
    [Show full text]
  • THE CROFTER, December 20131
    1 THE CROFTER, DECEMBER 20131 Scottish Crofting Federation THE CROFTER rooted in our communities The journal of the Scottish Crofting Federation, the only member-led organisation dedicated to the promotion of crofting and the largest association of small-scale food producers in the UK DECEMBER 2013 Number 101 Did the 2010 Questions on Scottish Act equalise availability of Government land sale policy OLLOWING THE Scottish Government's expressing an interest in the land, when, as crofting grants? decision to withdraw part of its Rosal the sales particulars were keen to point out, Fforest estate in Sutherland from communities were cleared from this land and open market sale after public criticism, the it is a deserted wilderness. ROFTING-SPECIFIC grants, SCF asked the government to examine its Putting this land on the market in this way is namely CCAGS and CHGS, policies on the sale of public land, community simply perpetuating a system of land ownership were expected to be extended to ownership and the creation of new crofts. concentrated into few hands, a system the C SCF chair Derek Flyn believes the Rosal Scottish people want to see changed.” owner-occupier crofters by virtue of the Crofting Reform (Scotland) Act 2010. case demonstrates some of the problems He continued “A great deal of effort and The former scheme provides grants caused by the manner in which the Forestry public money has been invested in reforming towards agricultural developments such Commission conducts the process of land crofting. The SG has pledged its commitment as sheds, barns, fencing and other sale. He said: “There is no surprise that to the crofting system and has legislated to permanent improvements; the latter local communities did not come forward Continued on page 3 towards the building of a croft house.
    [Show full text]
  • CB2013 Committee and Board Disclosureauditlist 9.10.13
    2013-2014 Conflict of Interest Disclosure AST Activity Participant First Name Participant Last Name Degree DisclosureDate Disclsoure Item Committee Member Reza Abdi MD 4/22/2013 No Relevant Financial Relationships Committee Member Sameh R. Abul-Ezz MD, PhD 4/16/2013 No Relevant Financial Relationships Committee Member Deborah B. Adey MD 4/15/2013 No Relevant Financial Relationships Committee Member Enver Akalin MD 4/16/2013 Consultant relationship with Pfizer Fellows 2013 Maria-Luisa Alegre MD, PhD 7/12/2013 No Relevant Financial Relationships Committee Member Alessandrini Alessandro PhD 4/29/2013 No Relevant Financial Relationships Board Member James S. Allan MD 5/3/2013 Committee Member No Relevant Financial Relationships Rita R. Alloway PharmD, FCCP Grant Support relationship with Astellas Grant Support relationship with BMS Grant Support relationship with Novartis Grant Support relationship with Lifecycle Grant Support relationship with Millenium Grant Support relationship with Pfizer (previously Wyeth) Grant Support relationship with Genentech (previously Roche) Board Member Grant Support relationship with Viropharma Committee Member Grant Support relationship with Alexion Fellows 2013 7/18/2013 Grant Support relationship with Sanofi (previously Genzyme, previously Sangstat) Committee Member Sandra Amaral MD, MHS 6/18/2013 Other relationship with Bristol Myers-Squibb Hatem Amer MD 5/6/2013 Grant Support relationship with Abbott Laborartories. Committee Member Other relationship with Massacheussetts Medical Society. Committee Member William Applegate No Relevant Financial Relationships Committee Member Alexander Aussi BSN, RN, MBA 4/22/2013 Consultant relationship with Total Transplant Advantage, LLC Committee Member Jamil Azzi MD 4/30/2013 No Relevant Financial Relationships Committee Member Fellows 2013 Mark L.
    [Show full text]
  • Pfizer's Bourla
    No. 3985 December 13, 2019 line success and business development. “In the next two years, we need to see how the pipeline is delivering,” he said. Bourla has been outspoken that when it comes to business development, he doesn’t see a mega-merger on the hori- zon. Instead, he said he is looking to bring in mid-stage clinical development assets to complement the internal pipeline. It sounds like investors can expect the company to be active on the business development front within those guard- rails. “I want to double it,” he said of the pipeline, which includes 92 projects right now. “And, we are going to double it by bringing in a lot of innovation to comple- ment what we distribute.” The company is focusing business de- velopment on six core therapeutic areas Pfizer’s Bourla: “I Think We Forgot as well, but Bourla indicated the company will be actively building out those areas both through internal investment and What It Looks Like To Grow” external collaboration. “We’re going to be JESSICA MERRILL [email protected] active because Pfizer is a very big plane and it cannot fly with one engine,” he said. fizer Inc. CEO Albert Bourla took in July it will merge the Upjohn business Bourla highlighted Pfizer’s recent acqui- over the top leadership spot from with Mylan NV to form a new generic drug sition of the cancer specialist Array Bio- PIan Read a year ago, but has quickly company to be called Viatris GMBH. Pharma for $11.4bn as an example of the executed on big changes poised to make The resulting Pfizer will be significantly kinds of deals the company will be pursu- Pfizer significantly smaller and faster smaller, with a 2020 annual revenue base ing.
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • Health Industry Business Communications Council
    Health Industry Business Communications Council Registered Labelers: Accredited Auto-ID Labeling Standards Argentina New MedTek Devices Pty Ltd Oxavita SRL Norseld Pty Ltd. Novadien Healthcare Pty Ltd The following companies Odontit S.A. (and/or their subsidiaries/ PAMPAMED S.R.L. Numedico Technologies Pty Ltd divisions) have applied PATEJIM SRL Opto Global Pty. Ltd. for a Labeler Identification Orthocell Limited Code (LIC) assignment with Austria Prolotus Technologies Pty Ltd HIBCC*. By doing so, they afreeze GmbH Red Milawa Pty Ltd dba Magic Mobility have demonstrated their AMI GmbH SDI Limited commitment to patient safety Bender Medsystems GmbH Signostics Ltd. and logistical efficiency for BHS Technologies GmbH Sirtex Medical Pty Ltd their customers, the industry Metasys Medizintechnik GmbH Smith & Nephew Surgical Pty. Ltd. and the public at large. PAA Laboratories GmbH Staminalift International Limited Safersonic Medizinprodukte Handels The Pipette Company Pty. Ltd. Any organization that is GmbH Thermo Electron Corporation interested in using the HIBC W & H Dentalwerk Burmoos GmbH Vush Pty Ltd uniform labeling system may apply for the assignment of VUSH STIMULATION Australia one or more LICs. William A Cook Australia Pty. Ltd. Adv. Surgical Design & Manufacture, Ltd. Last updated 9-21-2021 AirPhysio Pty Ltd Belgium Annalise-AI Pty Ltd 3M Europe Apollo Medical Imaging Technology Pty Advanced Medical Diagnostics SA/NV Ltd Analis SA/NV Benra Pty Ltd dba Gelflex Laboratories Baxter World Trade Bioclone Australia Pty. Ltd. Bio-Rad RSL Candelis, Inc. Bio-Rad Lab Inc Clinical Diag. Group DePuy Australia Pty. Ltd. Biosource Europe SA For more information, please dorsaVi Ltd Cilag NV contact the HIBCC office at: EC Certification Service GmbH Coris Bioconcept Fink Engineering Pty Ltd Fuji Hunt Photographic Chemicals NV 2525 E.
    [Show full text]
  • NFRF Stair Climb Sponsorship
    NATIONAL FIRST RESPONDERS FUND 2021 STAIR CLIMB PRESENTED BY Visit our website for more info! WHY WE CLIMB On a daily basis, Firefighters, Paramedics, and Police officers witness numerous tragic JOIN US ON 9/11/21 incidents while on duty. This recurrent, cumulative exposure to horrific events is the • Join us in person at 555 California Street in reason that more than 20% of First San Francisco, CA – or ANYWHERE virtually! Responders suffer from Post-traumatic Stress • Registration opens June 17, 2021 Injuries (PTSI). Treatment options are • Registration window is between June 17– available, but many of them are not covered September 11th by health insurance, and must be paid for out- • Our goal is to raise $250,000 of-pocket. Oftentimes, these costs are • Climb alongside heroes in one unforgettable prohibitive for a hero in need of help and can day to honor sacrifices made by First create obstacles for them to ask for the help. Responders Our goal is to eliminate the barriers and allow them to get the help they need. MEDIA REACH A $275,000 VALUE!* WHO WE ARE First Responders are there for us • Media Sponsor: Audacy on our worst days. The NFRF is a • Recorded promotional mentions on KLLC, KGMZ, 501C3 charitable organization KCBS, KITS, and KGMZ • Logo with station fundraising landing pages with founded to be there for them on drive to register/donate across all station websites their worst days (Tax ID# 82- • Event listings on all stations 3266569). We care for those who • 6x station eblasts (across cluster) with drive to care for us.
    [Show full text]
  • Federal Register/Vol. 84, No. 232/Tuesday, December 3, 2019
    Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices 66191 the Assistant Attorney General, patterns, devices, manufacturing filed with and accepted, subject to final developed the HSR Rules and the processes, or customer names. approval, by the Commission, has been corresponding Notification and Report placed on the public record for a period Form. Heather Hippsley, of thirty (30) days. The following On September 11, 2019, the Deputy General Counsel. Analysis to Aid Public Comment Commission sought comment on the [FR Doc. 2019–26075 Filed 12–2–19; 8:45 am] describes the terms of the consent reporting requirements associated with BILLING CODE 6750–01–P agreement and the allegations in the the HSR Rules and corresponding complaint. An electronic copy of the Notification and Report Form. 84 FR full text of the consent agreement 47951. No relevant comments were FEDERAL TRADE COMMISSION package can be obtained from the FTC received. Pursuant to the OMB [File No. 191 0061] Home Page (for November 15, 2019), on regulations, 5 CFR part 1320, that the World Wide Web, at https:// implement the PRA, 44 U.S.C. 3501 et Bristol-Myers Squibb Company and www.ftc.gov/news-events/commission- seq., the FTC is providing this second Celgene Corporation; Analysis of actions. opportunity for public comment while Agreement Containing Consent Orders You can file a comment online or on seeking OMB approval to renew the pre- To Aid Public Comment paper. For the Commission to consider existing clearance for those information your comment, we must receive it on or collection requirements.
    [Show full text]
  • RHS Supreme Champions 2017
    RHASS MAGAZINE SUMMER 2017 What a ShowStoppER! RHS Supreme Champions 2017: 8-page pullout + Post-Show Overview + New Members’ Area Survey + Technical Innovation Awards + Exhibitors Stories + RHASS Directors and Presidential Team 2017-18 + RHET Latest News + RHC Events to look out for RHASS • Society Magazine • Summer 2017 | 1 6 Contents COVER STORIES 6 Post-Show Overview 21 RHET News 24 RHC Events 13 26 RHASS Directors and Officials 2017 28 RHASS Presidential Team FEATURES 3 Welcome - Alan Laidlaw, Chief Executive 4 News Update 6 Royal Highland Show - Post-Show Analysis 21 8 Case Studies - “What the Royal Highland Show means to me...” 10 Technical Innovation Awards 13 Supreme Champions 2017 Pullout 21 Royal Highland Education Trust News 24 Royal Highland Centre Events 30 Members’ Feedback 24 RHASS MAGAZINE SUMMER 2017 CONTACT DETAILS: RHASS Society magazine Written & produced by is published by: The Royal Highland and Represent Agricultural Society of Scotland, Royal Highland 57 Calton Road, Centre, Ingliston, Edinburgh EH28 8NB Edinburgh EH8 8FJ Tel: (0131) 335 6200 [email protected] What a Email: [email protected] ShowStoppER! Web: www.rhass.org.uk RHS Supreme Champions 2017: 8-page pullout + Post-Show Overview + New Members’ Area Survey + Technical Innovation Awards + Exhibitors Stories Charity No. SC4561 + RHASS Directors and Presidential Team 2017-18 + RHET Latest News + RHC Events to look out for RHASS • Society Magazine • Summer 2017 | 1 2 | RHASS • Society Magazine • Summer 2017 Over 8,000 members attended the Show on each of the four days Welcome from RHASS Chief Executive Alan Laidlaw t is with pride that I reflect on my first Show as Chief Executive.
    [Show full text]
  • Register of GDP Sites 2019
    Register of GDP Sites 2019 Updated 16 August 2019 There are other sites authorised for wholesale dealing of veterinary medicinal products which do not appear on this register. These sites wholesale deal in both human and veterinary medicinal products and can be found on the MHRA section of GOV.UK: https://www.gov.uk/government/publications/human-and-vetinary-medicines- register-of-licensed-wholesale-distribution-sites-december-2014 Register of Authorised Wholesale Dealer Sites Authorisation Holder: WDA33618 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE, CW8 2AB SITE ID: S0415 ABBEYVET LLP 310 CHESTER ROAD, HARTFORD, NORTHWICH, CHESHIRE, CW8 2AB SITE ID: S0010 ABBEYVET LLP SHERBURN ENTERPRISE PARK, SHERBURN IN ELMET, LEEDS, WEST YORKSHIRE, LS25 6NB Authorisation Holder: WDA8599 AGRIHEALTH (N.I.) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN SITE ID: S0015 AGRIHEALTH (N.I.) LIMITED 9 SILVERWOOD INDUSTRIAL AREA, SILVERWOOD ROAD, LURGAN, CRAIGAVON, COUNTY ARMAGH, BT66 6LN Authorisation Holder: WDA5097 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKCALDY, FIFE, KY1 3NA SITE ID: S0456 ALBAVET LIMITED BUSINESS INCUBATOR OFFICE 21, MYREGORMIE PLACE, MITCHELSTON INDUSTRIAL ESTATE, KIRKCALDY, FIFE, KY1 3NA SITE ID: S0525 CVS GROUP PLC CVS HOUSE, OWEN ROAD, DISS, NORFOLK, IP22 4ER Authorisation Holder: WDA5030 ALBERT E JAMES & SON LIMITED BARROW MILL BARROW STREET, BARROW GURNEY, BRISTOL, BS48 3RU SITE ID: S0303 ALBERT E JAMES &
    [Show full text]
  • Stations Monitored
    Stations Monitored 10/01/2019 Format Call Letters Market Station Name Adult Contemporary WHBC-FM AKRON, OH MIX 94.1 Adult Contemporary WKDD-FM AKRON, OH 98.1 WKDD Adult Contemporary WRVE-FM ALBANY-SCHENECTADY-TROY, NY 99.5 THE RIVER Adult Contemporary WYJB-FM ALBANY-SCHENECTADY-TROY, NY B95.5 Adult Contemporary KDRF-FM ALBUQUERQUE, NM 103.3 eD FM Adult Contemporary KMGA-FM ALBUQUERQUE, NM 99.5 MAGIC FM Adult Contemporary KPEK-FM ALBUQUERQUE, NM 100.3 THE PEAK Adult Contemporary WLEV-FM ALLENTOWN-BETHLEHEM, PA 100.7 WLEV Adult Contemporary KMVN-FM ANCHORAGE, AK MOViN 105.7 Adult Contemporary KMXS-FM ANCHORAGE, AK MIX 103.1 Adult Contemporary WOXL-FS ASHEVILLE, NC MIX 96.5 Adult Contemporary WSB-FM ATLANTA, GA B98.5 Adult Contemporary WSTR-FM ATLANTA, GA STAR 94.1 Adult Contemporary WFPG-FM ATLANTIC CITY-CAPE MAY, NJ LITE ROCK 96.9 Adult Contemporary WSJO-FM ATLANTIC CITY-CAPE MAY, NJ SOJO 104.9 Adult Contemporary KAMX-FM AUSTIN, TX MIX 94.7 Adult Contemporary KBPA-FM AUSTIN, TX 103.5 BOB FM Adult Contemporary KKMJ-FM AUSTIN, TX MAJIC 95.5 Adult Contemporary WLIF-FM BALTIMORE, MD TODAY'S 101.9 Adult Contemporary WQSR-FM BALTIMORE, MD 102.7 JACK FM Adult Contemporary WWMX-FM BALTIMORE, MD MIX 106.5 Adult Contemporary KRVE-FM BATON ROUGE, LA 96.1 THE RIVER Adult Contemporary WMJY-FS BILOXI-GULFPORT-PASCAGOULA, MS MAGIC 93.7 Adult Contemporary WMJJ-FM BIRMINGHAM, AL MAGIC 96 Adult Contemporary KCIX-FM BOISE, ID MIX 106 Adult Contemporary KXLT-FM BOISE, ID LITE 107.9 Adult Contemporary WMJX-FM BOSTON, MA MAGIC 106.7 Adult Contemporary WWBX-FM
    [Show full text]